Abstract
A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 364-367 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 1997 |
Fingerprint
Keywords
- BCNU
- Central nervous system tumors
- Chemotherapy
- Cytoreductive surgery
- Interferon
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas. / Brandes, Alba Ariela; Scelzi, Elvira; Zampieri, Paolo; Rigon, Alberto; Rotilio, Antonino; Amista, Pietro; Berti, Franco; Fiorentino, Mario V.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 4, 08.1997, p. 364-367.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas
AU - Brandes, Alba Ariela
AU - Scelzi, Elvira
AU - Zampieri, Paolo
AU - Rigon, Alberto
AU - Rotilio, Antonino
AU - Amista, Pietro
AU - Berti, Franco
AU - Fiorentino, Mario V.
PY - 1997/8
Y1 - 1997/8
N2 - A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.
AB - A Phase II study with a combination of BCNU and α-interferon (IFN) was conducted in patients with high-grade glioma recurrent after surgery and radiation treatment in order to investigate tumor control and toxicity. Twenty-one non-chemotherapy pretreated patients were administered 6 MU α- IFN in a 2-h infusion followed by 150 mg/m2 BCNU i.v. on day 1. Three MU α- IFN were subsequently administered subcutaneously on alternating days three times a week, until recycling of the whole procedure on day 42. Among 21 patterns, partial remission was obtained in 7 (33%; 95% CI = 15-57) and stable disease in 6 (29%; CI = I 1-52); overall Kaplan-Meier median time to progression (TTP) was 4.5 months (CI = 4-9) and the overall median survival time (MST) was 7 months (CI 5-13). In patients who underwent surgical redebulking prior to chemotherapy, TTP and MST were 9 (CI = 7 - 14) and 15 months (CI = 11.039.0); in patients who were not operated on again before chemotherapy, these values were 4 (CI = 2- 5; log rank test, p = 0.0026) and 5.5 months (CI 4-7; log rank test, p = 0.0012) respectively. The results of this regimen in relapsing patients, especially following surgical redebulking, are encouraging; toxicity is acceptable, and further studies on combined α-IFN and multiple-agent chemotherapy are warranted.
KW - BCNU
KW - Central nervous system tumors
KW - Chemotherapy
KW - Cytoreductive surgery
KW - Interferon
UR - http://www.scopus.com/inward/record.url?scp=0030856633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030856633&partnerID=8YFLogxK
U2 - 10.1097/00000421-199708000-00008
DO - 10.1097/00000421-199708000-00008
M3 - Article
C2 - 9256890
AN - SCOPUS:0030856633
VL - 20
SP - 364
EP - 367
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 4
ER -